-

The myeloid cells targeting therapeutics market is anticipated to grow at a significant pace, till 2035, claims Roots Analysis

Published: April 2022


With the recent FDA approval of Tavenos™ for ANCA-associated vasculitis, myeloid cells have become an attractive target for pharmacological interventions, being developed for the treatment of various oncological disorders

London

Roots Analysis has announced the addition of “Myeloid Cell Targeting Therapeutics Market, 2021-2035” report to its list of offerings.

With ever increasing cancer burden, the focus of the research community has shifted towards the development of alternatives for the traditional anticancer therapies, such as myeloid cell targeting therapeutics. Myeloid cells, with their multifaceted functions and abundance in tumor microenvironment can be easily targeted and have emerged as novel therapeutic candidates for the treatment of several oncological disorders in combination with chemotherapy and radiotherapy.

To order this 150+ page report, which features 100+ figures and 5+ tables, please visit 
https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html

Key Market Insights

Presently, more than 100 drug candidates are being evaluated across different phases of development 
Over 70% of the pipeline candidates are currently being evaluated in clinical stages; of these, more than 35 candidates are in phase I of their clinical trials. This is followed by 25% therapies being investigated in preclinical and discovery stages. It is worth highlighting that majority of the therapy candidates (53%) are biologics. 

More than 380,000 patients have been enrolled in over 1,500 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, close to 65% have already been completed, while 22% are active and still recruiting patients.

Close to 10,000 articles focused on myeloid cells have been published, since 2016
Owing to the rising research efforts by several industry and non-industry players engaged in this domain, a number or peer reviewed articles have been published in reputed scientific journals. It is worth highlighting that, in 2021 (till June) 935 articles related to myeloid cells targeting therapeutics were published; of these more than 70% are research articles.

Close to 30 partnerships have been inked among various industry and non-industry players between 2017 and 2021
Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that, majority of the deals were R&D agreements, representing over 25% of the total number of partnerships signed.

Close to USD 5 billion has been invested by both private and public investors, since 2017
Of the total amount invested, over USD 2 billion was raised through secondary offering, representing over 58% of the overall funding activity in this domain. Further, 20 instances of venture capital funding were also reported, wherein players collectively received more than USD 750 million.

North America and Europe are anticipated to capture larger share of the market share by 2035
Growth in this domain is anticipated to be driven by the drugs that are being developed for the treatment of oncological and rare disorders. It is worth mentioning that myeloid cells targeting therapeutics market for small molecules is likely to capture over 70% of the total market share by 2035.

To request a sample copy / brochure of this report, please visit 
https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html

Key Questions Answered
  • Who are the leading players engaged in the development of myeloid cells targeting therapeutics?
  • Which are the key drugs being developed across early and late stages of development?
  • Which companies are actively involved in conducting clinical trials for myeloid cell targeting therapeutics?
  • What is the focus of various publications related to therapeutics targeting myeloid cells?
  • What kind of partnership models are commonly adopted by industry stakeholders engaged in the myeloid cells targeting therapeutics domain?
  • How is the current and future opportunity likely to be distributed across key market segments?     

The financial opportunity within the myeloid cells targeting therapeutics market has been analyzed across the following segments:

  • Type of Molecule
  • Small Molecule
  • Biologics
  • Type of Therapeutic Area
  • Oncological Disorders
  • Rare Disorders
  • Type of Therapy
  • Combination Therapy
  • Monotherapy
  • Route of Administration
  • Intravenous
  • Oral
  • Key Geographical Regions 
  • North America
  • Europe
  • Asia Pacific

The report features inputs from eminent industry stakeholder(s), who were very optimistic concerning the development of myeloid cells targeting therapeutics. The report includes detailed transcripts of the discussions held with the following industry experts:


The research also includes detailed profiles of the companies (listed below) engaged in developing therapies targeting myeloid cells; each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments, and an informed future outlook.

  • AstraZeneca
  • ChemoCentryx
  • Daiichi Sankyo
  • Enlivex
  • Gilead
  • GlaxoSmithKline
  • Immune-Onc Therapeutics
  • Infinity Pharmaceuticals
  • Jansen
  • Macrophage Pharma
  • Pfizer
  • Roche


For additional details, please visit 
https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html or email sales@rootsanalysis.com 

You may also be interested in the following titles: 
1.    Squamous Non-Small Cell Lung Cancer Market, 2021-2031
2.    Novel T-Cell Immunotherapies Market, 2021-2030
3.    HER2 Targeting Therapies Market, 2021-2030

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry